Receptor tyrosine-protein kinase erbB-2, also known as CD340 (cluster of differentiation 340), proto-oncogene Neu, Erbb2 (rodent), or ERBB2 (human) is a protein that in humans is encoded by the ERBB2 gene. One of the Receptor tyrosine kinases.
The ERBB2 gene is also frequently called HER2 (from human epidermal growth factor receptor 2) or HER2/neu.
HER2 is the target of the monoclonal antibody trastuzumab (marketed as Herceptin). Trastuzumab is effective only in cancers where HER2 is over-expressed. An important downstream effect of trastuzumab binding to HER2 is an increase in p27, a protein that halts cell proliferation. Another monoclonal antibody, Pertuzumab, which inhibits dimerization of HER2 and HER3 receptors, was approved by the FDA for use in combination with trastuzumab in June 2012.
Table of Contents
관련 논문 #
- Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor–directed therapies Nature Genetics 2018-12-10
Incoming Links #
Related Books (Book 0) #
Related Drugs (Drug 1) #
Related Articles (Article 2) #
- Lung cancer
- Receptor tyrosine kinase
- Triple-negative breast cancer
- 암 맞춤의학과 생물정보학
Related Education Events (EducationEvent 3) #
Related Medical Conditions (MedicalCondition 4) #
Related Medical Scholarly Articles (MedicalScholarlyArticle 5) #
- Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA
- Biomarkers in triple negative breast cancer: A review
- Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype
- Landscape of somatic mutations in 560 breast cancer whole-genome sequences
- Mechanisms underlying mutational signatures in human cancers
- The cancer genome
- The landscape of somatic copy-number alteration across human cancers